Caroline Seymour

April 14, 2022

Compared with Yervoy alone, the use of Yervoy plus Opdivo was associated with a significant survival benefit as a second-line treatment in patients with previously treated advanced melanoma, a type of skin cancer.

December 28, 2021

The use of Enhertu may also be beneficial across HER2-positive metastatic breast cancer subgroups including patients with and without brain metastases.

September 20, 2021

The average survival for patients with malignant pleural mesothelioma was less than a month after being diagnosed with COVID-19, according to a small study.

July 31, 2021

Fifteen percent of patients with myeloma did not have detectable antibodies two weeks after receiving the COVID-19 vaccine.

May 21, 2021

The data, according to an expert, show that treatment with Tecentriq could delay disease progression to an advanced stage, as well as the need for more aggressive therapy.

February 13, 2021

Treatment with sapanisertib was associated with limited activity and poor safety outcomes in patients with refractory metastatic renal cell carcinoma.

December 12, 2020

Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.

March 20, 2019

An expert discusses genetic profiling and other advances in the treatment of colorectal cancer.

February 05, 2019

Splitting up Darzalex dosing had comparable results to standard dosing schedules in patients with myeloma.

May 31, 2018

There are now three PARP inhibitors approved for the treatment of ovarian cancer, improving outcomes of many of the women who take them.